



NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

TO: _____ File _____

COMPANY: _____ N/A, see below _____

PAGES: _____ N/A _____ TEL.: _____ N/A _____

FAX #: _____ N/A _____

(630) 829-9892 FAX: (630) 515-1078

CONVERSATION RECORD

TIME		DATE
11:00 am		01/28/2011
NAME OF PERSON(S) CONTACTED	TELEPHONE NO.	ORGANIZATION
Brian Salisbury, Nuc. Med. Tech	(269) 686-4220	Allegan General Hospital
REPRESENTED PERSON or PERSONS		ORGANIZATION
Philip J. Hartgerink, M.D.		Allegan General Hospital
SUBJECT		
License No.: 21-18659-01		Control No.: 573790

SUMMARY

We reviewed the requesting renewal application and found that we were unable to continue this licensing action until we received additional information concerning the items noted below:

(1) The application was unclear as to whether PET is being used.

RESPONSE: The Contact Person indicated that PET is not in use.

(2) The cover letter to the application indicated that the Gd-153 sources are no longer in use. We noted that the sources will be left on the license until an amendment request is submitted, together with documentation indicating proper disposal and/or transfer of these sources, as required. The authorized use will be limited to storage, incident to disposal. Accordingly, Gd-153 will be removed for each Authorized User previously permitted to use these sources.

RESPONSE: The Contact Person indicated an understanding of the above statement.

(3) According to current NRC materials licensing policy, use limitations, such as cardiovascular clinical procedures and thyroid carcinoma treatment, are no longer listed on radioactive materials licenses. Accordingly, for each Authorizer User, 35.200 materials use authorizations will be listed without limitation. Similarly, AU James Lynch, M.D.'s, 35.300 materials use authorization will be modified to remove the exclusion of thyroid carcinoma. We required additional information as to whether Dr. Lynch's use of 35.300 materials is limited to 33 mCi or less of I-131.

RESPONSE: The Contact Person indicated an understanding of the policy changes noted above. Concerning Dr. Lynch's 35.300 materials use, the Contact Person indicated that use generally does not exceed 12 mCi of I-131. The Contact Person indicated that it would be appropriate to limit Dr. Lynch's 35.300 authorization to 33 mCi or less of I-131. This concurs with the 35.300 limitation for the other AU with 35.300 authorization, Philip J. Hartgerink, M.D.

Based on the responses noted above, no further action is required at this time.

NAME OF PERSON DOCUMENTING CONVERSATION
Sara A.B. Forster

SIGNATURE

DATE

Sara A.B. Forster

02/07/2011

J. Forster 3/9/11